Rheumatology

Why Cheaper Humira Alternatives Face Resistance

Adalimumab biosimilars cut NHS spend by over 50% while treating more patients. NOR-SWITCH and subsequent trials consistently show switching from reference biologic to biosimilar is safe. Sarah Mitchell and James Carter explain the regulatory science, the no...

Stopping Spinal Fusion Or Protecting The Gut?

PsA is not RA with skin, and axSpA is not RA in the spine. The biologic hierarchy shifts significantly across the spondyloarthropathy spectrum - IL-17 and IL-23 inhibitors dominate, anti-TNF has uveitis caveats, and IBD comorbidity changes everything. Sarah...

Chasing Absolute Zero In Rheumatoid Arthritis

Treat-to-target transformed RA outcomes - not through new drugs but through rigorous measurement and escalation discipline. Sarah Mitchell and James Carter cover the evidence base, the disease activity tools, the window of opportunity in early RA, and when ...

The ORAL Surveillance JAK Inhibitor Controversy

ORAL Surveillance showed tofacitinib carried higher cardiovascular and malignancy risk than anti-TNF in high-risk RA patients - triggering a class-wide boxed warning. But was the signal overgeneralised? Sarah Mitchell and James Carter unpack the data, the c...

Multidisciplinary Care Improves Spondyloarthritis Outcomes

A multidisciplinary approach to spondyloarthritis, addressing both articular and extra-musculoskeletal manifestations, improves patient outcomes.

Guselkumab Label Adds Psoriatic Arthritis Structural Damage Inhibition

Guselkumab (Tremfya) has received an updated label to include inhibition of structural damage progression in psoriatic arthritis.

EULAR 2026: Key Rheumatology Trials to Watch

Anticipated trials at EULAR 2026 will address unmet needs in psoriatic arthritis and systemic lupus erythematosus, focusing on novel therapeutic targets.

Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions

Early identification of interstitial lung disease (ILD) in systemic autoimmune rheumatic diseases (SARD) and systemic sclerosis (SSc) is critical.

Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026

Achieving early disease control in systemic lupus erythematosus (SLE) is critical for preventing organ damage. Targeting the interferon (IFN) pathway offers a precise therapeutic strategy.

Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk

Treat-to-target strategies in Systemic Lupus Erythematosus (SLE) aim for optimal disease control but introduce patient burden and potential risks.